Stocks / Alpha Vantage News Sentiment

RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370

RBC Capital has reiterated its Buy rating on Amgen (AMGN.US) and maintained its target price at $370. This indicates a continued positive outlook from the analyst firm on the biotechnology company's stock performance.